Sernova (TSE:SVA) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sernova Corp., a clinical-stage biotech company, has canceled its public offering due to unfavorable market conditions, believing that the current market does not reflect the company’s value. CEO Cynthia Pussinen states that they are looking for more favorable financing options while remaining focused on advancing their Cell Pouch System™ technology, which has shown promise in a Phase I/II study for treating insulin-dependent diabetes.
For further insights into TSE:SVA stock, check out TipRanks’ Stock Analysis page.